New drug combo tested in fight against tough ovarian cancer
NCT ID NCT05053750
Summary
This small, early-stage study is testing if adding a bone drug (zoledronic acid) to standard chemotherapy (paclitaxel and bevacizumab) helps control recurrent ovarian cancer that has stopped responding to platinum drugs. It will involve about 14 women to see if the three-drug combination changes immune cells in the tumor and is safe. The main goal is to gather information to see if this approach is worth studying in larger trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.